CAS: 298197-04-3

Fatostatin is a benzylic diacid compound that has been extensively studied for its potential therapeutic uses. It is known to inhibit the activity of c-myc, a gene that plays a crucial role in cell growth and division. Fatostatin has shown promising results as an anti-cancer agent, particularly in the treatment of various types of tumors. It exhibits cytotoxic effects on cancer cells and has been found to induce apoptosis, or programmed cell death. In addition to its anti-cancer properties, Fatostatin has also demonstrated inhibitory effects on the production of polysialic acid, which is involved in cell adhesion and migration. This makes it a potential candidate for the treatment of diseases characterized by abnormal cell proliferation and migration. Furthermore, Fatostatin has shown inhibitory activity against thymidylate synthase, an enzyme involved in DNA synthesis. This property makes it a potential candidate for combination therapy with other chemotherapeutic agents. Overall, Fatostatin is a promising research

Fatostatin hydrobromide (Fatostatin A HBr), an inhibitor of sterol regulatory element binding protein (SREBP), impairs the activation of SREBP-1 and SREBP-2.

2-(2-Propylpyridin-4-Yl)-4-(P-Tolyl)Thiazole Hydrobromide

Fatostatin hydrobromide